Kamran Alam
2023 - Taysha Gene Therapies
In 2023, Kamran Alam earned a total compensation of $975.4K as Chief Financial Officer at Taysha Gene Therapies, a 19% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $148,950 |
|---|---|
| Option Awards | $402,039 |
| Salary | $413,751 |
| Other | $10,661 |
| Total | $975,401 |
Alam received $413.8K in salary, accounting for 42% of the total pay in 2023.
Alam also received $149K in non-equity incentive plan, $402K in option awards and $10.7K in other compensation.
Rankings
In 2023, Kamran Alam's compensation ranked 1,244th out of 3,001 executives tracked by ExecPay. In other words, Alam earned more than 58.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,244 out of 3,001 | 59th |
Division Manufacturing | 736 out of 1,645 | 55th |
Major group Chemicals And Allied Products | 492 out of 913 | 46th |
Industry group Drugs | 480 out of 876 | 45th |
Industry Biological Products, Except Diagnostic Substances | 138 out of 211 | 35th |
Source: SEC filing on April 18, 2024.
Alam's colleagues
We found two more compensation records of executives who worked with Kamran Alam at Taysha Gene Therapies in 2023.
News
Taysha Gene Therapies CEO Sean Nolan's 2023 pay slips 20% to $1.5M
April 18, 2024
Taysha Gene Therapies CEO RA Session's 2022 pay falls 57% to $2M
May 8, 2023
Taysha Gene Therapies CEO RA Session's 2021 pay slips 3% to $4.6M
April 28, 2022
Inotek Pharmaceuticals CEO Gaurav Shah's 2019 pay falls 39% to $3.9M
April 24, 2020
Aquinox Pharmaceuticals CEO Jonathan Drachman receives $3.8M in 2019
March 24, 2020
Aquinox Pharmaceuticals CEO David Main's 2018 pay jumps 39% to $4.2M
October 2, 2019